Abstract:BACKGROUND The minimum inhaled gas absolute humidity level is 20 mgH2O l−1 for short-duration use in general anaesthesia and 30 mgH2O l−1 for long-duration use in intensive care to avoid respiratory tract dehydration. OBJECTIVE The aim is to compare the effects of different fresh gas flows (FGFs) through a circle rebreathing system with or without a heat and moisture exchanger (HME) on inhaled gas absolute humidity in adults undergoing general anaesthesia. DESIGN Systematic review and meta-analyses of randomised controlled trials. We defined FGF (l min−1) as minimal (0.25 to 0.5), low (0.6 to 1.0) or high (≥2). We extracted the inhaled gas absolute humidity data at 60 and 120 min after connection of the patient to the breathing circuit. The effect size is expressed as the mean differences and corresponding 95% confidence intervals (CI). DATA SOURCES PubMed, EMBASE, SciELO, LILACS and CENTRAL until January 2017. RESULTS We included 10 studies. The inhaled gas absolute humidity was higher with minimal flow compared with low flow at 120 min [mean differences 2.51 (95%CI: 0.32 to 4.70); P = 0.02] but not at 60 min [mean differences 2.95 (95%CI: −0.95 to 6.84); P = 0.14], and higher with low flow compared with high flow at 120 min [mean differences 7.19 (95%CI: 4.53 to 9.86); P < 0.001]. An inhaled gas absolute humidity minimum of 20 mgH2O l−1 was attained with minimal flow at all times but not with low or high flows. An HME increased the inhaled gas absolute humidity: with minimal flow at 120 min [mean differences 8.49 (95%CI: 1.15 to 15.84); P = 0.02]; with low flow at 60 min [mean differences 9.87 (95%CI: 3.18 to 16.57); P = 0.04] and 120 min [mean differences 7.19 (95%CI: 3.29 to 11.10); P = 0.003]; and with high flow of 2 l min−1 at 60 min [mean differences 6.46 (95%CI: 4.05 to 8.86); P < 0.001] and of 3 l min−1 at 120 min [mean differences 12.18 (95%CI: 6.89 to 17.47); P < 0.001]. The inhaled gas absolute humidity data attained or were near 30 mgH2O l−1 when an HME was used at all FGFs and times. CONCLUSION All intubated patients should receive a HME with low or high flows. With minimal flow, a HME adds cost and is not needed to achieve an appropriate inhaled gas absolute humidity.

End-to-End Influence Maximization in the Field

Abnormal trace metals in man: cadmium.

Processing Specular Reflection Components of Chrome-plated Surface by Multi-Image Reconstruction Method

Recognition of single-stranded nucleic acids by small-molecule splicing modulators

Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy

Specificity, synergy, and mechanisms of splice-modifying drugs

Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C.

Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy

Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers

Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.

Patient-specific responses to SMN2 splice-modifying treatments in spinal muscular atrophy fibroblasts

[Environment and development of epidemics. New biologic epidemic occurrences].

Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA)

Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology

Effects of different fresh gas flows with or without a heat and moisture exchanger on inhaled gas humidity in adults undergoing general anaesthesia: A systematic review and meta-analysis of randomised controlled trials

An Ontology-Based Affective Computing Approach for Passenger Safety Engagement on Cruise Ships

Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of SMN2 in SMA Type I Fibroblasts

Effects of Inhibitors of SLC9A-Type Sodium-Proton Exchangers on Survival Motor Neuron 2 (SMN2) mRNA Splicing and Expression

Time of action of neuroprotectors plays a role?

Addressing Today’s Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam

A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein